Health Policy and Technology最新文献

{"title":"Is Poland ready for the European health data space?","authors":"Katarzyna Byszek,&nbsp;Barbara Więckowska,&nbsp;Anna Gawrońska,&nbsp;Katarzyna Luchowska","doi":"10.1016/j.hlpt.2026.101167","DOIUrl":"10.1016/j.hlpt.2026.101167","url":null,"abstract":"<div><h3>Objectives</h3><div>The European Health Data Space (EHDS) aims to enhance cross-border data sharing across the EU for care continuity and innovation. This research aims to identify strengths, weaknesses, opportunities, and threats related to effective EHDS implementation, considering perspectives of researchers, IT, and health experts.</div></div><div><h3>Methods</h3><div>A narrative literature review and expert interviews with eight Polish stakeholders from diverse sectors were conducted. Findings were synthesized using a dynamic SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis supported by MAXQDA-assisted qualitative coding.</div></div><div><h3>Results</h3><div>Strengths included Poland’s experience in large e-health projects linked to digital health resources, stakeholder awareness of standards, and research capabilities. Major weaknesses involved infrastructural gaps, fragmented standards, and resistance to change. Opportunities related to funding and international collaboration, while threats involved regulatory uncertainty, cybersecurity, and lack of public trust. The dynamic SWOT analysis revealed that strengths significantly outweigh weaknesses and improve readiness for EHDS. However, infrastructural limitations and funding risks remain highly influential negative factors.</div></div><div><h3>Conclusions</h3><div>Poland shows strong potential for EHDS implementation, particularly through leveraging e-health experience and data analytics. Addressing internal limitations and increasing public trust are essential for maximizing EHDS benefits and mitigating risks.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101167"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trust during COVID-19: comparing two high-trust countries with different pandemic strategies","authors":"Adrian Kellner,&nbsp;Eli Feiring,&nbsp;Terje P. Hagen","doi":"10.1016/j.hlpt.2026.101170","DOIUrl":"10.1016/j.hlpt.2026.101170","url":null,"abstract":"<div><h3>Objectives</h3><div>Sweden and Norway, two high-trust countries sharing many cultural similarities, adopted notably different strategies in the initial phase of the COVID-19 pandemic. While Sweden relied on a mitigation strategy emphasising individual responsibility, Norway swiftly imposed strict restrictions. This study aimed to examine whether levels of political and social trust differed between the two countries, whether trust changed from before to after the pandemic, and whether any changes differed between the countries in ways consistent with their divergent pandemic strategies.</div></div><div><h3>Methods</h3><div>We analysed data from the repeated cross-sectional European Social Survey (ESS) covering rounds from 2018/19 and 2022/23 to assess levels and changes in political and social trust in Sweden and Norway. In parallel, we used data from the VaxPref survey (2022–2023), a cross-sectional survey, to examine how trust in public health authorities, newspapers, and social media related to COVID-19 infection and individual characteristics. Variation in trust was analysed using ordinary least squares regression models.</div></div><div><h3>Results</h3><div>Political and social trust were high in both countries, though consistently higher in Norway than in Sweden both before and after the pandemic. Trust levels remained stable over time in both countries, with no significant changes between the pre-pandemic and post-pandemic periods. We found no differential trends between Sweden and Norway that could be attributed to their different pandemic strategies. COVID-19 infection was not associated with trust levels in either country.</div></div><div><h3>Conclusion</h3><div>Despite their markedly different pandemic management strategies, both countries exhibited stable levels of political and social trust throughout the period studied. The findings suggest a sustained rally-around-the-flag effect in both high-trust societies, indicating that the choice of pandemic strategy, whether strict lockdowns or voluntary compliance, did not undermine trust in institutions or fellow citizens.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101170"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond timing: A critical review of the iTUG test and its implementation challenges for fall risk assessment in community-dwelling older adults","authors":"U. Medina U Luis ,&nbsp;Montefusco S Rodrigo ,&nbsp;Saavedra S Cristhian ,&nbsp;San Martín C Mauricio","doi":"10.1016/j.hlpt.2026.101166","DOIUrl":"10.1016/j.hlpt.2026.101166","url":null,"abstract":"<div><h3>Objectives</h3><div>Falls are a major cause of morbidity in community‑dwelling older adults. The Timed Up and Go (TUG) test is widely used to assess mobility and fall risk, but its single time‑based outcome limits diagnostic sensitivity. The instrumented TUG (iTUG) augments this assessment using inertial sensors to derive subphase‑specific metrics. This critical review evaluates the methodological robustness and implementation readiness of iTUG and outlines strategies for its integration into routine care.</div></div><div><h3>Methods</h3><div>Structured searches in Web of Science, Scopus, and PubMed Central (2000–2025) identified English‑language, peer‑reviewed iTUG studies in predominantly older or community‑dwelling adults. Eligible studies used sensor‑based or otherwise instrumented TUG assessments and reported fall‑risk or clinically relevant implementation aspects; forty‑two were appraised with MMAT 2018, and findings were synthesized narratively and organized within a SWOT framework.</div></div><div><h3>Results</h3><div>iTUG metrics showed good validity for global duration and straight‑walking segments but weaker performance for short transitional phases. Subphase‑level outcomes were often more sensitive than total time to age‑ and risk‑related differences yet marked heterogeneity in protocols and reported variables limited comparability and precluded meta‑analysis. Evidence on added prognostic value, real‑world clinical impact, and primary‑care implementation was insufficient, while external barriers included unclear reimbursement pathways, fragmented regulatory guidance, and limited clinician training.</div></div><div><h3>Conclusions</h3><div>Current iTUG research demonstrates clear technical potential but important methodological and implementation gaps. Progress towards routine use will require protocol and outcome standardization, pragmatic implementation studies, and alignment of regulatory and reimbursement frameworks within broader digital health and fall‑prevention strategies.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101166"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public preferences for vaccination programs in Russia: insights from a discrete choice experiment","authors":"Aregawi G. Gebremariam ,&nbsp;Beidemaryam W. Admasu ,&nbsp;Dereje Abegaz ,&nbsp;Atnafu Gebremeskel Sore ,&nbsp;Francesco Paolucci","doi":"10.1016/j.hlpt.2026.101154","DOIUrl":"10.1016/j.hlpt.2026.101154","url":null,"abstract":"<div><h3>Objectives</h3><div>This study examined public preferences for COVID-19 vaccines in Russia to inform future pandemic strategies, contextualizing within the country’s unique historical and socio-political landscape.</div></div><div><h3>Methods</h3><div>A nationally representative Discrete Choice Experiment (DCE) was conducted with 3,010 Russian respondents. Participants evaluated hypothetical vaccine profiles varying across attributes: effectiveness, side-effect risk, protection duration, origin, approval time, social restrictions, and mandates. Preferences were analysed using a Multinomial Logit (MNL) model and a Latent Class Model (LCM) to capture heterogeneity.</div></div><div><h3>Results</h3><div>Respondents preferred vaccines with higher effectiveness (60%, 70% and 90% vs. 40%) and longer protection. Severe side effects significantly reduced vaccine appeal. Russian-made vaccines were strongly favoured, while EU, UK, and US vaccines were less preferred. Vaccines with shorter approval times were preferred. Less stringent social restrictions and mandates were also preferred. The LCM identified two classes: a pro-vaccine group (52%) responsive to both vaccine and policy attributes, and a non-supportive group (48%) more sceptical and likely to opt out. Trust in institutions, vaccine attitudes, and political values significantly influenced class membership.</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccine preferences in Russia reflected concerns over efficacy, safety, origin, and governance. Nationalistic attitudes and historical mistrust toward foreign institutions may have shaped preferences. Policy tools such as mandates were more effective when paired with high-quality vaccines. Tailored communication and community-based engagement are essential to address diverse concerns and promote uptake.</div></div><div><h3>Lay Summary</h3><div>We asked over 3,000 people in Russia to choose between different COVID-19 vaccine options and related policies. People preferred vaccines that worked well, protected for longer, and had a low chance of serious side effects. Many strongly preferred vaccines made in Russia over those from other countries, showing pride in local science and possible distrust of foreign sources. They also liked vaccines that were approved quickly and linked to fewer social restrictions. We found two main groups: just over half were generally in favour of vaccination, while almost half were more doubtful and often chose not to vaccinate. Trust in government, healthcare, and political views were key factors in these decisions. To improve vaccine uptake in future health crises, it will be important to provide safe, effective vaccines and to communicate in ways that address the concerns of both supportive and sceptical groups.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101154"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SITeCard: A human-centric explainable intelligent system to support the cardiovascular rehabilitation process","authors":"Romina Torres ,&nbsp;Marcelo Tuesta ,&nbsp;Carolina Saavedra ,&nbsp;Diego Mellado ,&nbsp;Bastian Carvajal ,&nbsp;Christopher Zurita ,&nbsp;Catalina Valle ,&nbsp;Matías Salinas ,&nbsp;Marvin Querales ,&nbsp;Oneglio Pedemonte ,&nbsp;Rodrigo Salas ,&nbsp;Orietta Nicolis","doi":"10.1016/j.hlpt.2026.101168","DOIUrl":"10.1016/j.hlpt.2026.101168","url":null,"abstract":"<div><h3>Objectives</h3><div>To report the development and early formative, user-centered evaluation of a human-centric explainable artificial intelligence (AI)-enabled platform for remote and hybrid phase II cardiovascular rehabilitation (CR), and to discuss its policy and technology implications for adoption and governance in health systems facing access constraints.</div></div><div><h3>Methods</h3><div>A four-stage methodology was applied: (1) multidisciplinary needs elicitation with cardiovascular rehabilitation professionals; (2) development of machine-learning models for rehabilitation-related risk assessment with integrated explainability; (3) adaptation of expla-nations to clinicians’ and patients’ mental models; and (4) system implementation followed by early multidisciplinary evaluation focused on usability, perceived clinical utility, and safety positioning as a second-opinion decision support tool.</div></div><div><h3>Results</h3><div>The platform integrates remote patient monitoring, explainable risk assessment, and coordinated multidisciplinary workflows. In early formative evaluation, healthcare professionals reported high acceptance of the explainable second-opinion functionality, highlighting improved interpretability and support for rehabilitation assessment and discharge-related discussions, without replacing clinical judgment.</div></div><div><h3>Conclusions</h3><div>This study provides an early-stage, policy-relevant account of how explainable AI can be operationalized in cardiovascular rehabilitation while remaining aligned with clinical practice and governance expectations. Rather than demonstrating system-level impact, the con-tribution lies in outlining a practical framework for evaluating adoption conditions, governance needs, and future scale-up of AI-enabled rehabilitation technologies.</div></div><div><h3>Public interest summary</h3><div>Cardiovascular rehabilitation helps people recover after a heart event, but many patients face barriers to attending in-person programs, particularly due to distance, mobility, or limited service availability. SITeCard is a digital platform developed to support remote and hybrid cardiovascular rehabilitation by organizing patient data and providing clinicians with explainable AI-based risk assessments to inform multidisciplinary discussions. The system was co-designed with healthcare teams to ensure usability and clinically meaningful explanations, and it can be accessed through standard smartphones, including in low-connectivity settings. This study reports early, user-centered evaluation results and highlights policy and governance considerations relevant to the adoption of explainable AI tools in rehabilitation services.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101168"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A discount rate for economic evaluations for Health Technology Assessment in Greece","authors":"Kostas Athanasakis ,&nbsp;Marios Athanasios Loupas ,&nbsp;Ilias Kyriopoulos","doi":"10.1016/j.hlpt.2026.101169","DOIUrl":"10.1016/j.hlpt.2026.101169","url":null,"abstract":"<div><h3>Objectives</h3><div>Health Technology Assessment (HTA) is a cornerstone of evidence-based decision-making in healthcare, with Economic Evaluation (EE) constituting an integral part of this process. A key methodological parameter in EEs is the discount rate, which allows for consistent valuation of future costs and benefits. In this study, we use Greece as a case study to provide an empirically grounded estimation of a country-specific social discount rate (SDR), combining international best practices with national economic conditions, projections and societal preferences.</div></div><div><h3>Methods</h3><div>For the analysis, we employ the Social Rate of Time Preference framework via an extended version of the Ramsey formula. The model parameters, i.e. pure rate of time preference, elasticity of marginal utility of consumption, expected per capita consumption growth, and the variance of consumption growth, were estimated based on national datasets on mortality, taxation, GDP growth, and demographic trends. The base-case estimate of the SDR was tested for robustness through a series of one-way sensitivity analyses (OWSA).</div></div><div><h3>Results</h3><div>The base-case estimate for the SDR in Greece was estimated at 3.42%. The OWSA revealed that the SDR was mostly influenced by variations in expected per capita consumption growth and pure rate of time preference.</div></div><div><h3>Conclusion</h3><div>This study provides an empirically grounded estimate of a country-specific social discount rate for Greece. The estimated value, lies well within interanationally used values in EEs. Our analysis underlines the importance of macroeconomic evidence and trends and highlights the need of future/periodic reassessments of the SDR to maintain alignment with economic and societal changes.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101169"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the full potential of real-world evidence in pharmacoeconomic analyses: A framework for adoption","authors":"Kamaljeet,&nbsp;Abhishek Vijukumar,&nbsp;Sourabh Kosey","doi":"10.1016/j.hlpt.2026.101165","DOIUrl":"10.1016/j.hlpt.2026.101165","url":null,"abstract":"<div><h3>Background</h3><div>RWE is an essential complement to RCTs, enhancing external validity, reflect long-term outcomes, and reflect the everyday clinical practice. RWE is increasingly being integrated into the decision-making process of health technology assessment (HTA) agencies and payers worldwide; however, methodological, ethical, and operational barriers remain.</div></div><div><h3>Aim</h3><div>The aim of this review is to propose a five-pillar to support the systematic and transparent integration of RWE into pharmacoeconomic evaluation and to demonstrate policy relevance through cross-national case studies.</div></div><div><h3>Methods</h3><div>A narrative analysis was conducted, based on the literature identified in PubMed, Scopus, Web of science, and Google scholar (2015–2024), as well as policy documents obtained at HTA bodies. Inclusion criteria focused on studies an reports addressing the use of RWE in pharmacoeconomic or HTA. Sweden, Germany, and Canada were selected as the case studies to illustrate the registry-based, digital health-driven, and post-launch reimbursement models to RWE implementation. The five-pillar framework was developed through synthesis of these sources and cross-referencing with existing guidance, including ISPOR Good Practices, STaRT-RWE, CanREValue.</div></div><div><h3>Findings</h3><div>The proposed framework is structured around five pillars: data preparedness and infrastructure, methodological rigour, analytical integration in economic models, stakeholder alignment and transparency, and governance, ethics, and lifecycle feedback. The framework adds value beyond existing approaches by emphasizing data interoperability, ethical safeguards, and adaptive real-time reassessment. The case studies illustrated the enhancement of external validity in oncology (Sweden), the facilitation of adaptive reimbursement processes of digital health interventions (Germany), and the post-launch funding modification in rheumatology (Canada) through RWE.</div></div><div><h3>Conclusion</h3><div>RWE can be integrated in pharmacoeconomic analyses through a systematic, policy-relevant approach defined by the five-pillar framework. Despite the limitation associated with a narrative review design and the focus on high-income country examples, it sets up a basis on which future empirical validation in diverse contexts, including low- and middle-income countries. Such practices have the potential to enhance inclusiveness, transparency, and sustainability in healthcare decision-making within an era of value based care.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101165"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination preferences and predictors of vaccine hesitancy in Brazil: A discrete choice experiment","authors":"Ana Rita Sequeira ,&nbsp;Marcello Antonini ,&nbsp;Bernardo Andretti","doi":"10.1016/j.hlpt.2026.101156","DOIUrl":"10.1016/j.hlpt.2026.101156","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study investigates the extent to which individual characteristics and preferences towards vaccine attributes and societal restrictions influence vaccination behaviour in a representative Brazilian population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;We conducted a discrete choice experiment (DCE) involving 3,001 Brazilian respondents from July to September 2022 through an online panel. The DCE involved five vaccine features and two social restriction features. Participants were presented to a sequence of binary choices of hypothetical vaccination programs, with an option to opt-out. We performed multiple regression models to investigate the predictors of vaccination and opt-out decisions. We also performed a latent class logit model to estimate trade-offs between vaccination attributes and societal restrictions across groups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Our regression results identified that gender, religiosity, income, political orientation and trust in public health institutions were important predictors of vaccination decisions in Brazil. Our latent class models indicated significant heterogeneity and detected four main classes: (i) left-leaning, pro restrictions, who showed strong preferences for vaccine features such as its effectiveness (62.4%); (ii) left-leaning, pro mandates, who showed strong support for societal restrictions (19.5%); (iii) centrists, pragmatics, who were opposed to restrictions but supportive of vaccine features (11.4%); (iv) right-leaning, vaccine refusers, who showed a willingness to opt-out from vaccination programmes and did not show any preferences for vaccine features (6.7%).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Our findings suggest that the Brazilian population had overall high willingness to accept vaccines and displayed high trust in public health authorities. Nonetheless, the presence of a non-negligible proportion of cautious and hesitant groups may prevent the effectiveness of vaccination campaigns in the future.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Lay summary&lt;/h3&gt;&lt;div&gt;This study investigated the factors that influence people’s decisions to get vaccinated in Brazil. We asked 3,001 participants to choose between different vaccination programs with various features, including vaccine effectiveness and the presence of social restrictions. We found that factors such as gender, income, religion, political views, and trust in public health institutions affected people’s vaccination decisions. The study also identified four groups: one strongly supports vaccines and their characteristics, one supports both vaccines and social restrictions, another prefers vaccines but dislikes restrictions, and a fourth is more hesitant-refuser about vaccines and more likely to opt out of vaccination. Overall, most Brazilians showed high trust in vaccines and public health advice. However, a small but significant group remains hesitant and refusing, which could pose challenges for future vaccination efforts","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 3","pages":"Article 101156"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions, attitudes, and intention to adopt artificial intelligence in healthcare among medical and pharmacy students","authors":"Luu Thi Thuy ,&nbsp;Hoang Thi Ngoc Sen ,&nbsp;Nguyen Huong Giang ,&nbsp;Huynh Huu Bon ,&nbsp;Vo Thi Ngoc Ha","doi":"10.1016/j.hlpt.2025.101145","DOIUrl":"10.1016/j.hlpt.2025.101145","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to describe medical and pharmacy students' perceptions, attitudes, and intention to adopt artificial intelligence (AI) in healthcare and identify factors influencing their intention to use AI.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in Vietnam in December 2024 using a convenience sampling strategy. A self-administered questionnaire was employed to evaluate students’ perceptions of AI applications, attitudes toward AI, and their intention to integrate AI into healthcare. Hierarchical regression analysis was carried out to identify significant factors influencing intention.</div></div><div><h3>Results</h3><div>Most participants acknowledged AI’s advantages, with 66.9 % recognizing its role in patient documentation, 63.5 % agreeing it supports preventative health recommendations, and 61.9 % endorsing its contribution to capacity planning. However, skepticism remained, as 28.1 % doubted AI’s effectiveness in psychiatric counseling, 25.7 % questioned its application in surgery, and 22.0 % were uncertain about its ability to analyze patient data for prognoses. Attitudinally, 63.1 % expressed concern over AI’s impact on job security, though 47.2 % maintained a generally positive outlook on AI’s role in healthcare. Over half of the respondents expressed a strong willingness to integrate AI into their future practice, with 60.1 % affirming their intent to use AI-based technology. Hierarchical regression analysis highlighted attitudes toward AI (ß = 0.528), perceptions of AI in individual patient care (ß = 0.207), and self-assessed technology skills (ß = -0.121) as significant predictors of intention.</div></div><div><h3>Conclusions</h3><div>Attitudes, perceptions of AI in individual patient care, and technology skills strongly influenced students’ intention to adopt AI. Integrating AI education into medical curricula may improve preparedness for AI-driven healthcare.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 2","pages":"Article 101145"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN project","authors":"Carin A. Uyl-de Groot ,&nbsp;Nicolas S.H. Xander ,&nbsp;Tom Belleman ,&nbsp;Emily A. Burger ,&nbsp;Robin Doeswijk ,&nbsp;Isabelle Durand-Zaleski ,&nbsp;Benjamin P. Geisler ,&nbsp;Oliver Groene ,&nbsp;Anne Hendrickx ,&nbsp;Pia S. Henkel ,&nbsp;Renaud Heine ,&nbsp;Mirjana Huić ,&nbsp;Mauro Melli ,&nbsp;Kate Morgan ,&nbsp;Monica Racovița ,&nbsp;Gauthier Quinonez ,&nbsp;Maureen P.M.H. Rutten-van Mölken ,&nbsp;Tomáš Tesař ,&nbsp;Frederick W. Thielen ,&nbsp;Peter Schneider ,&nbsp;Eline Aas","doi":"10.1016/j.hlpt.2026.101155","DOIUrl":"10.1016/j.hlpt.2026.101155","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;Disparities in access to potential innovative health technologies (pIHTs) persist across Europe due to differing healthcare budgets, pricing policies, and health technology assessment (HTA) practices. The ASCERTAIN project aims to reduce these inequalities by developing integrated pricing, cost-effectiveness, and reimbursement approaches that enhance affordability, long-term sustainability, and timely patient access.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The project applies a mixed-methods approach, including literature review, stakeholder surveys, interviews, and focus groups, to ensure relevance across diverse health systems. It integrates access-based pricing, value-driven HTA, and adaptable reimbursement models into a practical, open-access ACCESS2MEDS Toolbox. This includes access-based pricing frameworks, cost-effectiveness models, and budget impact and reimbursement analyses, all adaptable to country-specific conditions to reduce uncertainty and improve transparency. Tools are co-created with patients, developers, clinicians, and policymakers and will be tested and validated using three use cases representing high-impact areas of innovation: precision oncology medicines, cell and gene therapies, and next-generation sequencing tests.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Outputs will include validated tools enabling improved evaluation of clinical benefit, cost-effectiveness, and financial sustainability, strengthening value-based decision-making across Europe. Innovative access- and outcome-based pricing strategies will support responsible innovation while encouraging fair reimbursement and improved budget control. Policy roadmaps will guide the adoption of equitable access models and support system-level implementation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;ASCERTAIN will provide a harmonized framework that balances cost control, innovation incentives, and patient-centered care. By facilitating consistent, evidence-based pricing and reimbursement decisions, the project supports fair and sustainable access to pIHTs across Europe, with continued multi-stakeholder collaboration driving its wider adoption and real-world impact.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Public interest abstract&lt;/h3&gt;&lt;div&gt;Many lifesaving medical breakthroughs, like advanced cancer therapies and gene treatments, are becoming available, but not everyone in Europe can access them equally. Differences in healthcare funding and pricing decisions mean that patients in some countries wait much longer for the care they need. The ASCERTAIN project is working to change this. By bringing together patients, health technology developers, clinicians, and policymakers, the project is creating new tools to help health systems decide how to pay for cutting-edge technologies in a fair and affordable way. These tools also make sure that these technologies are paid for based on how well they work for patients in real life. By improving transparency and reducing financial pr","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"15 2","pages":"Article 101155"},"PeriodicalIF":3.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}